← All trials
NCT00659373
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2007
- Primary completion
- Dec 1, 2014
- Completion date
- Apr 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 86
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- International Breast Cancer Study GroupLead sponsor
- International Breast Cancer Study GroupStudy chair
- National Cancer Institute (NCI)Collaborator
- Australia and New Zealand Breast Cancer Trials GroupCollaborator
- Cancer and Leukemia Group B (CALGB)Study chair
- Cancer and Leukemia Group B (CALGB)Collaborator
- Peter MacCallum Cancer CentreStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.